BNGO

On March 23, 2026, Bionano Genomics reported Q4 2025 financial results, with the stock seeing a significant daily move of +27%. On May 13, 2026, the company reported Q1 2026 financial results, showing total revenue of $6.7 million (up 4% year-over-year) and a 17% increase in nanochannel array flow cell sales, also providing Q2 and full-year 2026 revenue guidance. On June 18, 2026, Bionano announced a 67% year-over-year growth in studies featuring Optical Genome Mapping at ESHG 2026, indicating expanding global adoption. On June 24, 2026, the company announced the hiring of a Chief Scientific Officer. On August 10, 2026, Bionano reported Q2 2026 results, with revenue of $8.2 million (up 21% year-over-year) and consumables revenue up 31%, and fully retired all outstanding Senior Secured Convertible Debentures, removing secured debt; full-year 2026 revenue guidance was raised to $31-$33 million. In August 2026, the interim CEO purchased 4,000 shares of BNGO stock. On September 14, 2026, Bionano announced three new peer-reviewed studies demonstrating the clinical value of OGM across myelodysplastic syndromes and acute myeloid leukemia, presented at the H.C. Wainwright 28th Annual Global Investment Conference, and news indicated cost cuts of 71% targeting positive EBITDA, though more funding is still needed. On September 23, 2026, Bionano Laboratories announced the expansion of OGM-based diagnostic testing for hematologic malignancies at Memorial Sloan Kettering Cancer Center, following New York State Department of Health approval.